Key result
Serum thromboxane B2 level measurement detected ASA resistance in 8.6% of patients compared to 41.9% with impedance aggregometry, demonstrating weak correlation (r = 0.443; P < 0.0001).
Why the study?
What is the percentage of ASA resistance in CABG patients when measured by serum thromboxane B2 level versus impedance aggregometry?
Observational (n=105)
What is the percentage of ASA resistance in CABG patients when measured by serum thromboxane B2 level versus impedance aggregometry?
Effect estimate: r = 0.443
Absolute Event Rate: 8.6% vs 41.9%
p-value: p=<0.0001
Different platelet function tests yield significantly different rates of ASA resistance in CABG patients, highlighting the challenge of standardizing antiplatelet monitoring.
ASA resistance rates in CABG patients vary markedly by assay; leaves open standardization of monitoring and requires prospective outcome validation.
Cardiovascular patients take acetylsalicylic acid (ASA) for preventing myocardial infarction and other thromboembolic complications. It is already known that in some patients this therapy is not effective. The aim of this study was to assess the percentage of ASA resistance on the sample of patients with coronary artery bypass grafting. Our study included 105 patients with coronary artery bypass grafting treated with ASA 150 mg/day or lesser. Platelet aggregation was measured by serum thromboxane B2 level as well as impedance aggregometry from whole blood to determine ASA antiaggregation effect. The percentage of ASA resistance was 41.9% with impedance aggregometry, and after determining the serum thromboxane B2 level this percentage was only 8.6%. The correlation between these two methods was weak (r = 0.443; P < 0.0001). Thromboembolic complications still occur in ASA-treated patients because some patients are resistant to ASA therapy. It would be useful to monitor the effectiveness of ASA therapy and give another antiaggregation drug to these patients to reduce adverse events. The problem is which test is ideal because different tests show different percentages of ASA resistance.
No takes yet. Share an insight, caveat, or question.
Klasić et al. (2015) conducted an observational in Coronary artery bypass grafting (n=105). Serum thromboxane B2 level measurement vs. Impedance aggregometry was evaluated on Percentage of ASA resistance (r = 0.443, p=<0.0001). Serum thromboxane B2 level measurement detected ASA resistance in 8.6% of patients compared to 41.9% with impedance aggregometry, demonstrating weak correlation (r = 0.443; P < 0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: